Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Allschwil, Switzerland, May 28, 2026

Ad hoc announcement pursuant to Art. 53 LR

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 13.3 million to Basilea to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis.

David Veitch, Chief Executive Officer of Basilea, said: “Basilea is proud to be developing ceftibuten-ledaborbactam in partnership with BARDA. This funding helps us to further advance this novel antibiotic, including the preparation of the clinical phase 3 program. By advancing this promising candidate, we are potentially addressing the critical unmet need for the oral treatment of cUTIs caused by multidrug-resistant Gram-negative bacteria.”

After the current tranche of USD 13.3 million, a total of USD 25 million have been committed by BARDA. The contract^[1] could provide up to USD 133 million of additional non-dilutive funding.

Full PR available here